Nilo Therapeutics

Nilo Therapeutics is a New York-based, preclinical-stage biotechnology company pioneering a differentiated approach to immunomodulation by targeting the neural circuits that regulate systemic inflammation. Building on seminal discoveries from the laboratories of Charles Zuker (Columbia University / HHMI), Ruslan Medzhitov (Yale), and Stephen Liberles (Harvard) that identified vagal neurons regulating systemic immune activation, and led by CEO Kim Seth, the company harnesses the body-brain axis to restore immune homeostasis centrally, moving beyond conventional immunosuppression to treat autoimmune and inflammatory disease. Nilo launched in 2025 with a $101M Series A co-led by DCVC Bio, Lux Capital, and The Column Group, with participation from Alexandria Venture Investments and the Gates Foundation. As a therapeutics company it publishes no public developer API, SDK, or developer portal surface.

Nilo Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Immunology, and Neuroscience.

🌐 Visit website 📡 Source on GitHub

3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyBiotechnologyTherapeuticsImmunologyNeuroscienceDrug DiscoveryPharmaceuticalsHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 3.3/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/nilo-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 2

The organization behind the API

Website

Website

LinkedIn

Source (apis.yml)

aid: nilo-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/nilo-therapeutics.png
name: Nilo Therapeutics
description: Nilo Therapeutics is a New York-based, preclinical-stage biotechnology company pioneering a differentiated approach
  to immunomodulation by targeting the neural circuits that regulate systemic inflammation. Building on seminal discoveries
  from the laboratories of Charles Zuker (Columbia University / HHMI), Ruslan Medzhitov (Yale), and Stephen Liberles (Harvard)
  that identified vagal neurons regulating systemic immune activation, and led by CEO Kim Seth, the company harnesses the
  body-brain axis to restore immune homeostasis centrally, moving beyond conventional immunosuppression to treat autoimmune
  and inflammatory disease. Nilo launched in 2025 with a $101M Series A co-led by DCVC Bio, Lux Capital, and The Column Group,
  with participation from Alexandria Venture Investments and the Gates Foundation. As a therapeutics company it publishes
  no public developer API, SDK, or developer portal surface.
url: https://raw.githubusercontent.com/api-evangelist/nilo-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Therapeutics
- Immunology
- Neuroscience
- Drug Discovery
- Pharmaceuticals
- Healthcare
common:
- type: DomainSecurity
  url: security/nilo-therapeutics-domain-security.yml
- type: Website
  url: https://www.nilotx.com/
- type: LinkedIn
  url: https://www.linkedin.com/company/nilo-therapeutics
apis: []
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io

Nilo Therapeutics

Kin Score

Security Posture 1

Nilo Therapeutics Domain Security

Resources

Access & Security 1

Company 2

Source (apis.yml)